ACR25 Best Abstracts - Day 1 Save

The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expected but some of these are gems. 

2 year extension data from SELECT-GCA:

Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo

Higher rates zoster, CK elevation in UPA group#ACR25 @RheumNow #ACRBest pic.twitter.com/jf8Dh2wCBj

— Brian Jaros, MD (@Dr_Brian_MD) October 26, 2025

Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow#ACR25 Abstr#0776 #ACRBest pic.twitter.com/MgRo7kIgIw

— Richard Conway (@RichardPAConway) October 26, 2025

Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA)

Pts in remission re-randomized at wk52

Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%)

Argues strongly for continuing tx in GCA for >1yr!@RheumNow #ACR25 Ab#0776 #ACRBest pic.twitter.com/exmmIcpgbP

— Mike Putman (@EBRheum) October 26, 2025

Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early bx. 

Risk factor = low c3/c4

Urine biomarkers promising#ACRBest #ACR25 @RheumNow pic.twitter.com/WuNPKeqeid

— Brian Jaros, MD (@Dr_Brian_MD) October 26, 2025

#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment)

- 71% had LN (No class IV or Mixed)
- 46% actionable LN

Cost-effectiveness data needed.#ACRBest @RheumNow pic.twitter.com/Bt3fuA3aJh

— Md Yuzaiful Md Yusof (@Yuz6Yusof) October 26, 2025

High prevalence of sleep related symptoms in PsA pts! 
-Snoring 53% 
-Morning fatigue 68% 
-Obstructive Sleep Apnea in 50% 
14% mild 19% moderate 17% severe 

Estimated prevalence 36% 

No correlation between OSA and PsA disease activity or comorbidities 
But small cohort!… pic.twitter.com/VKe7qcHIRm

— Aurelie Najm (@AurelieRheumo) October 26, 2025